Floatz logo

3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE

Stroke, Not Specified as Hemorrhage or Infarction

Burnasyan Federal Medical Biophysical CenterSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Stroke, Not Specified as Hemorrhage or Infarction cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Rivaroxaban
China National Center for Cardiovascular Diseases
Phase 4BBB

View all 50 →

Same molecule, other indications

3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE is also rated in:

myocardial ischemiaDormant
BB
Indicative ·
69 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
kidney cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →